Molecular Basis of Insulin Resistance and Its Relation to Metabolic Syndrome by Arora, Sarika
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books










© 2012 Altieri et al., licensee InTech. This is an open access chapter distributed under the terms of the 
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
The Metabolic Syndrome in Hispanics –  
The Role of Insulin Resistance and Inflammation 
Pablo I. Altieri, José M. Marcial, Nelson Escobales,  
María Crespo and Héctor L. Banchs 
Additional information is available at the end of the chapter 
http://dx.doi.org/10.5772/50337 
1. Introduction 
The acknowledgment of the metabolic syndrome (MetS) as a pathological entity is one of the 
most important advancements in the management of cardiovascular disease in the last 2 
decades. Increasing awareness and research of this syndrome has led to a deeper 
understanding of how different metabolic risk factors such as inflammation, insulin 
resistance and vascular pathologies such as coronary heart disease (CHD) interact and 
aggravate one another. The existence of MetS may imply uniformity in pathology across a 
range of populations. However, this is not the case: the mechanisms that underlie MetS and 
the cardiometabolic consequences they hold may very well vary between ethnicities. The 
following chapter aims to encompass MetS from its most fundamental principles with a 
focus on inflammation and insulin resistance to the novel research pertaining to its 
pathophysiology and management, with an emphatic eye on the Hispanic population. 
2. Metabolic syndrome in Hispanics 
The inner workings of MetS have yet to be fully elucidated; thus it remains difficult to 
evaluate how they differ between specific ethnic populations. Nevertheless, it remains a 
possibility that the processes involved in the syndrome, such as insulin resistance and 
inflammation, differ in degree and function with relation to Hispanic compared to non- 
Hispanic populations. It has been a recurring theme that the interactions between poor 
nutritional status, physical inactivity, and genetic predisposition might contribute to the 
disparities in the prevalence and characteristics of MetS and its components between 
ethnicities and the subgroups within; this subject has been studied to the extent that even 
the diagnostic criteria for MetS established by the AHA/NHLBI were challenged when 
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adapted to a specific Andean population[1]. Moreover, researchers have found that a single 
DNA variation in the form of a guanine base pair on a gene already linked to a higher risk of 
Coronary Heart Disease (CHD) in other races confers a fivefold reduction in risk in African-
Americans[2]. Lately, research has uncovered mutations in the Brain-derived neurotrophic 
factor (BDNF) gene, or Bdnf gene, which result in human obesity[58]. Mice having a truncated 
long Bdnf 3′ UTR genetic transcript developed severe hyperphagic obesity. In these mice, the 
ability of the adipocytokine leptin to activate hypothalamic neurons and inhibit food intake 
was compromised despite normal activation of leptin receptors. All these studies, whether 
they involve humans or mice, provide a window into a genetic basis for MetS. 
Despite the obvious limits of studying a population that does not represent the entire 
Hispanic world, investigations exploring cardiovascular disease and MetS in Puerto Ricans 
provide invaluable information in understanding the interrelationship between genetics, 
environment and culture in the modification of cardiovascular health. Previous data support 
the fact that, given the same cardiovascular risk factors, Puerto Rico has a lower prevalence 
of CHD than other fully industrialized countries such as the United States[3]; however, the 
validity of these data may not be as strong today as when published nearly 3 decades ago: 
recent epidemiologic data show that, although mortality from CHD and stroke has been 
steadily decreasing in the United States in the past 4 decades, it has been increasing in 
Puerto Rico[4]. On the other hand, a recent investigation that examined the medical records 
of 173 patients with MetS who received treatment in the Cardiovascular Center of Puerto 
Rico and the Caribbean showed that these patients were devoid of aggressive CHD, 
meaning less ventricular tachycardia, less myocardial infarctions and less strokes, and had a 
relatively normal lipid profile (except for a mild elevation in serum triglycerides)[5], 
supporting the notion that island-based Puerto Ricans acquire a milder form of MetS than 
mainland populations (this notion extends to Hispanics and Caucasians living in the 
continental U.S.).[6] Furthermore, several investigators have reported that the incidence of 
ventricular tachycardia, a complication caused by remodeling and ischemia of the heart, is 
lower in Puerto Rico than in the United States[7], even when adjusting for a higher 
prevalence of MetS in Puerto Rico[8]. Interestingly, the number of cases recorded in this 
study showed an increased incidence of atrial fibrillation[9]; this may be thought to be a 
result of differential remodelling of the left ventricle and atrial function between ethnicities. 
In addition, the prevalence of CHD is lower in Puerto Rico than in the United States, despite 
a higher incidence of Diabetes Mellitus in the island than in the U.S. (16% vs. 8%)[10]. 
Nonetheless, the prevalence of CHD in Puerto Rico is increasing: In the 1980s, it was 50% 
lower than in the United States; it is only 20% lower today[10]. This is most likely due to 
external factors such as the increasingly unhealthy diet and sedentary lifestyle of many of 
the island’s inhabitants. 
3. Importance of the Renin-Angiotensin System (RAS) 
The RAS is a complicated and essential system in the regulation of vascular homeostasis. 
Angiotensin II (AngII) is cleaved from angiotensin I (AngI) by angiotensin converting 
 
The Metabolic Syndrome in Hispanics – The Role of Insulin Resistance and Inflammation 77 
enzyme (ACE), which is localized on the surface of endothelial cells and in the media and 
adventia of the aorta[11]; a soluble form of ACE is also found in plasma. AngI is formed from 
angiotensinogen, which is secreted from the liver and cleaved by renin, which in turn is 
found in the juxta-glomerular cells in the kidney[12]. The traditional RAS inhibitors, 
angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor 
blockers (ARBs), target the main RAS axis described above. However, there are additional 
enzymes associated with the production of AngII, such as by Cathepsin G[13], as well as 
other, more novel angiotensin molecules that serve as potential therapeutic targets: the 
ACE2/Ang-(1–9) axis is a new and important pathway to compensate for the 
vasoconstrictive and hyperproliferative RAS axis. A direct mechanism implicated in the 
production of these distinctive angiontensin molecules involves ACE2[14], a novel 
component of the RAS that converts AngI to Ang-(1-9) and AngII to Ang-(1-7), a peptide 
with vasodilator and anti-proliferative properties. The induction of ACE2 not only holds 
therapeutic promise by producing the anti-inflammatory Ang-(1-7), but also by reducing 
AngII levels, thereby conferring a twofold protection against cardiovascular remodeling 
from ongoing hypertension and inflammation. 
Concomitant to the progression of the RAS, hyperglycemia promotes the deposition of 
advanced glycation end products (AGEs) that are formed from the non-enzymatic glycation 
of proteins and lipids after contact with reducing sugars[15]. The accumulation of AGEs is an 
important factor in the development and progression of vascular injury in diabetes-
associated atherosclerosis. Both hyperglycemia and induction of the main RAS axis will 
increase oxidative stress and increase the rate of the atherosclerotic process that ultimately 
end in apoptosis and necrosis of myocytes[16, 17], hence propagating the deleterious effects of 
inflammation, insulin resistance and endothelial dysfunction. 
The inhibition of the RAS by ACE inhibitors and ARBs has been mainstay therapy to reduce 
the onset and/or progression of hypertension, left ventricular dysfunction, diabetic renal 
disease and atherosclerosis. For example, inhibitors of the RAS seem to be more effective 
than other medications in halting the progression of dilated cardiomyopathy in hamsters 
that have an inherited mutation that predisposes to such a disease[18]. In rodents, 
pharmacological or genetic disruption of RAS action prevents weight-gain, promotes insulin 
sensitivity and relieves hypertension[19], suggesting that ACE inhibitors or ARBs may 
present an effective treatment for MetS in humans. In addition, when obese individuals lose 
weight, both adipose tissue mass and systemic RAS activity are reduced[20,21]. An increase in 
adipose tissue angiotensinogen has been reported in diet-induced obesity[22,23]: further 
evidence that lifestyle changes are integral to targeting the underlying mechanisms of MetS.  
4. Inflammation and insulin resistance 
Systemic inflammation[24-25] is a fundamental process in the development of cardiovascular 
disease in patients with MetS, and this process starts with the activation of the neuro-
hormonal system; we have data that shows elevated intra-coronary levels of AngII and 
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endothelin I (EI) in some patients with Diabetes Mellitus Type 2 (DMT2). We measured 
these peptides in 5 patients with DMT2 and concomitant MetS, normal coronary arteries 
and sub-normal ejection fraction (49 ± 5%), and discovered that the levels of AngII and EI 
were elevated in the coronary sinus (coronary efflux) and aorta of these patients when 
compared to the control group, which consisted of 5 patients with DMT2 but without MetS 
that were catheterized and found to have normal coronary arteries and a normal ejection 
fraction[26]. In the former, MetS group, AngII levels inside the coronary sinus and aorta were 
46 ± 18 and 35 ± 15 pg/ml, respectively, while AngII levels were 10 ± 2 pg/ml inside both 
chambers of the control group (P < 0.001). Furthermore, in the group with MetS, the EI levels 
inside the coronary sinus and aorta were elevated at 14 ± 4 and 13 ± 6 pg/ml in both 
chambers, respectively, compared to 3 ± 1 pg/ml inside both chambers of the control group 
(P < 0.001).  
This elevation of AngII and EI will activate angiotensin II receptor type 1 (AT1) and produce 
inflammatory cytokines, increase macrophage chemo-attractants and activate reactive 
oxygen species that produce oxidative stress in myocytes and smooth muscle cells[27]. This 
will not only induce the apoptosis and necrosis of myocytes, but also promote the 
proliferation and migration of smooth muscle cells, resulting in the atherosclerotic lesions 
that increase the incidence of myocardial infarcts[28]. Likewise, AngII, acting via angiotensin 
II receptor type 2 (AT2), has potent pro-inflammatory, pro-oxidant and pro-thrombotic 
effects[29]. Moreover, it has been shown that infusion of AngII in rats increases serum levels 
of AGEs. The oxidative and apoptotic effects of both hyperglycemia and AngII are most 
likely key in inducing diabetic cardiomyopathy[27,28], which explains why our patients with 
MetS have a subnormal ejection fraction, as opposed to the patients without MetS who have 
a normal ejection fraction, despite normal coronary arteries in both groups.  
Omega-3, eicosapentaenoic acid (EPA) and docosahexaenoic acid (OHA) have also been 
shown to be anti-inflammatory; they are enzymatically converted to resolvins, which are very 
potent anti-inflammatory agents[30]. Resolvins diminish the activation and production of 
superoxide, increase nitric oxide and decrease inflammatory cytokines- this mechanism will 
counterbalance inflammation and, as a consequence, insulin resistance. It has been shown that 
Omega-3 in high doses will reduce the incidence of myocardial infarction and, in some 
patients, revert insulin resistance. We have reported the normalization of the 2-hour post-
prandial levels of blood sugar with the use of Omega-3[6]. The mean 2-hour post-prandial 
glucose levels in 10 patients decreased from a mean value of 205±40mg/dl to 119±13mg/dl 
(P<0.003). This change occurred after using 6000mg per day of pure Omega-3 for about 6 
months. The effect of Omega-3 is mediated through the insulin receptors of the cells. At 
present, we are studying these receptors in order to explain this increase in insulin sensibility.  
Adipose tissue is a hormonally active endocrine tissue, producing cytokines, which 
influence other body tissues. Adiponectin is one such adipocytokine that protects 
cardiovascular tissue from ischemic injury and increases insulin sensitivity by stimulating 
fatty acid oxidation, decreasing plasma triglycerides and improving glucose metabolism[33,34]. 
Another adipocytokine, secreted-frizzled-related-protein-5 (Sfrp5), has been found to have 
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significant metabolic consequences; incorporation of Wnt signaling pathways, which 
classically regulate developmental processes in many organisms, in adipocytes has led to 
evidence that obesity induces a reduction in the Sfrp5 production along with an increase in 
Wnt5a expression, leading to augmented inflammatory signalling and insulin resistance[36]. 
Conversely, Sfrp5 acts as an anti-inflammatory molecule, restraining the chronic inflammatory 
state and improving insulin sensitivity. On the other hand, tumor necrosis factor- α (TNF-α) 
and interleukin-6 (IL-6) are insulin antagonizing adipocytokines[37] that are associated to 
augmentation of inflammation and insulin resistance. As seen, inflammation is a complicated 
issue in obesity that has to be stopped due to deleterious effects produced in the 
cardiovascular system, such as the reduction in ejection fraction observed in our sample of 
patients with MetS and normal coronaries: a diabetic cardiomyopathy undoubtedly brought 
on by chronic inflammation and insulin resistance[40].  
Insulin resistance is a fundamental mechanism underlying MetS and its components. Insulin 
is an anabolic hormone that exerts its effects primarily by promoting glycogen synthesis in 
the liver and muscle, increasing triglyceride synthesis in adipose tissue, and augmenting 
protein synthesis and inhibiting proteolysis. Therefore, the consequences of insulin 
resistance are multiple-fold. Truly, there are other processes involved in the development of 
insulin resistance other than inflammation. Abnormalities in fat storage and mobilization 
have been implicated in the pathogenesis of insulin resistance[38]. Abdominal obesity in 
particular has been shown to be most associated with insulin resistance and MetS. However, 
it has been observed that general obesity is not universal in MetS and insulin resistance. In 
addition, many obese subjects do not have metabolic abnormalities. Systemic chronic 
inflammation[39], on the other hand, paints the most complete picture of insulin resistance as 
it is the result of all altered cytokine production and signaling pathways in the body. A more 
accessible marker for this inflammation can be obtained by measuring C-reactive protein 
(CRP); 40% of our patients with MetS had an elevated CRP. Clinically, each of the diagnostic 
component criteria of the metabolic syndrome has been associated with increased levels of 
CRP[41], elevation of which bears a negative prognostic implication in the population 
involved - this biomarker has been associated to the development of heart disease, although 
this observation is not totally clear[31,32]. CRP production is located in the liver, a process 
induced by pro-inflammatory cytokines; this non-specific marker of inflammation has an 
important role in the host innate defense mechanism, but also regulates the amount of 
inflammatory response by activating the complement system. CRP can be used to monitor 
the status of the inflammatory system, and has been used to monitor the effect of statins in 
the inflammatory process of MetS[35]. In the Jupiter trial, rosuvastatin (20mg/day) reduced 
the systemic marker of CRP.  
Finally, a novel and important piece in the development of insulin resistance consists of 
aldosterone-induced insulin resistance through the increase in insulin-like growth factor-1 
(IGF-1) and hybrid receptors[42]. This research has demonstrated that aldosterone induces 
vascular remodeling through the IGF-1 and hybrid receptors and suggests that blocking the 
effects of aldosterone may attenuate and reduce angiopathy in hypertensive patients with 
hyperinsulinemia.  
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5. Circadian rhythm and the metabolic syndrome 
Common disorders of circadian behavior and sleep, such as night-shift work and jetlag, are 
associated with increased hunger, decreased glucose and lipid metabolism and changes in 
hormonal processes involved in satiety[43]. Short-duration and poor-quality sleep have been 
shown to predict the development of DMT2 and obesity after age, BMI and various other 
confounding variables are considered and taken into account[44]. In addition, the induction 
of hunger may be associated to a reduction in circulating levels of leptin brought on by sleep 
deprivation[45]. Cardiovascular disease and hypertension are also related with sleep loss, as 
the risk of a fatal heart attack increases 45% in individuals who chronically sleep 5 hours per 
night or less[46]. Disruption of the circadian clock can lead to obesity, inflammation and 
insulin resistance[47]. 
6. Management 
6.1. Diet and exercise 
Lifestyle approaches to treating and preventing MetS greatly improve metabolic parameters 
by reducing body weight and increasing the level of physical activity. Multiple studies of 
obese patients with DMT2, hypertension or hypercholesterolemia have shown that weight 
improves the cardiovascular profile, including glycemic control, in both diabetic and non-
diabetic individuals. Furthermore, lifestyle changes[48] comprising reduced total/saturated fat 
intake and increased polyunsaturated fat/fiber intake have been shown to significantly 
reduce multiple metabolic and inflammatory parameters such as CRP, central obesity and 
triglyceride levels. The ATTICA[49] epidemiological study showed that adherence to the 
Mediterranean diet was associated with 20% lower odds of having MetS, irrespective of age, 
sex, physical activity, lipids and blood pressure levels. On the other hand, consumption of a 
high fat diet induces changes in the fat microbia, producing inflammation that is associated 
with hyperphagia and an obese phenotype. In addition, data on the Hispanic and Asian 
diets with relation to diabetes have demonstrated that rice consumption is associated to an 
elevated risk of developing DMT2, presumably due to the higher glycemic index of rice 
when compared to whole grain[50]. Physical activity is a cornerstone in weight balance. 
However, only part of the beneficial effect of physical activity on the metabolic and 
cardiovascular profile is mediated through body weight changes. Physical activity improves 
insulin sensitivity, increases HDL levels, lowers blood pressure and maintains immune 
system health, which is very important in reducing inflammation and, as a consequence, 
insulin resistance[51]. 
6.2. Pharmacotherapy 
Although intensified therapeutic lifestyle modifications may prevent the onset and 
progression of MetS, some patients may require drug therapy. While the individual 
components (e.g. glucose intolerance, hypertension, dyslipidemia) are all appropriate 
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targets for treatment, newer therapies that manage the syndrome centrally may benefit from 
such a collective approach and thus prove more effective. Although traditional approaches 
to the separate risk factors have proven effective, increasing attention is now being directed 
at the management of insulin resistance, obesity and inflammation. Orlistat, sibutramine, 
and rimonabant are approved for long-term treatment of obesity; however, sibutramine is 
known to cause secondary hypertension and thus is not the ideal choice of therapy in obese 
patients with MetS. As was mentioned above, statins and RAS inhibitors have proven anti-
inflammatory properties that may augment insulin sensitivity. Glitazones and metformin 
have been used increasingly over the recent years for the management of insulin resistance. 
The ongoing search for new strategies to combat the MetS has shed light on new molecules 
that may prove to be effective therapeutic targets in treating the syndrome; in vivo studies 
have established that atherosclerosis driven by the inhibition of stearoyl-coenzyme A 
desaturase 1 (SCD1), an enzyme involved in fatty acid metabolism, can be completely 
prevented by the omega-3 polyunsaturated fatty acids in dietary fish-oils[52]. Moreover, our 
data showing that in some patients, high doses of omega-3 polyunsaturated fatty acids will 
normalize the 2-hour post-prandial glucose levels in a sample from Puerto Rico is 
promising. 
6.3. Bariatric surgery 
Given that lifestyle changes and pharmacology may not be sufficient to achieve durable and 
effective weight loss, surgery to treat obesity and MetS has become an attractive alternative. 
In addition to weight loss, patients may enjoy improvement in other metabolic parameters 
such as insulin resistance and other obesity-related comorbidies. Bariatric surgery has been 
shown to reverse diabetes, hypertension, sleep apnea and hyperlipidemia[53], however, 
selection of candidates must be a strict process in view of peri- and postoperative 
complications and costs associated with different surgical procedures. 
7. Social importance 
The economic cost of combating obesity and associated comorbidies is estimated to exceed 
$100 billion annually in the United States[54]. With recent data showing the increasing 
burden of obesity throughout the world, it can be expected that the rates of MetS will be 
increasing. A study that aims to assess the independent contributions of MetS and its 
individual components to 10-year medical costs among a sample of elderly individuals 
showed that total costs to Medicare were 20% higher among participants with the MetS[55]. 
Another study found that risk factors for metabolic syndrome, such as obesity, high blood 
pressure, and elevated blood lipid levels, can increase a person's healthcare costs nearly 1.6-
fold, or about $2,000 per year; for each additional risk factor those costs rise an average of 
24%[56]. These figures are even more alarming in the context of the prevalence of the MetS in 
relation to socio-economic position: social class has been shown to have an inverse relation 
to MetS[57]. 
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8. Conclusion 
In an age when millions of people are estimated to be afflicted by the MetS, new 
perspectives into this cluster of risk factors are imperative if we are to evolve its 
management: the focus on inflammation and insulin resistance is crucial in order to halt or 
delay the disease as soon as it is detected. Moreover, the public health of Hispanic 
populations throughout the world has been evidenced to pose a significant public health 
problem that should be addressed specifically because of the distinct metabolic 
characteristics this ethnicity may hold. Likewise, this approach should prompt further 
investigation into parallel cardiometabolic particularities in other ethnicities. 
Author details 
Pablo I. Altieri, José M. Marcial, Nelson Escobales, María Crespo and Héctor L. Banchs 
Department of Medicine and Physiology, University of Puerto Rico, Medical Sciences Campus,  
San Juan, Puerto Rico and The Cardiovascular Center of Puerto Rico and the Caribbean, Puerto Rico  
9. References 
[1] Medina-Lezama, J., et al. Optimal definitions for abdominal obesity and the metabolic 
syndrome in Andean Hispanics: the PREVENCION study. Diabetes Care 33, 1385-1388 
(2010). 
[2] Brian G. Kral, R.A.M., Bhoom Suktitipat, Ingo Ruczinski, Dhananjay Vaiya, Lisa R. 
Yanek, Arshed A. Quyyumi, Riyaz S. Patel, A Maziar Zafari, Viola Vaccarino, Elizabeth 
R. Hauser, William E. Kraus, Lewes C. Becker, Diane M. Becker. A common variant in 
the CD2KN2B gene on chromosome 9p21 protects against coronary artery disease in 
Americans of African ancestry. Journal of Human Genetics (2011). 
[3] Garcia Palmieri MR, C.R., Cruz VW, Cortes AM, Colon A, Filiberty M, Ayala AM, 
PAttern D, Sobrino R, Torres R, Navarro M. Risk factors and prevalence of Coronary 
Heart Disease in Puerto Rico. Circulation 42, 541-542 (1970). 
[4] Capewell, S., et al. Cardiovascular risk factor trends and potential for reducing coronary 
heart disease mortality in the United States of America. Bull World Health Organ 88, 120-
130 (2010). 
[5] Altieri P, B.H., Escobales N, Crespo M & Figueroa Y A Less Aggressive Metabolic 
Syndrome In Puerto Rico than in the United States. J Investigative Med. 2009: P2. 
[6] Altieri P, B.H., Escobales N & Crespo M. . Metabolic Syndrome - Variability In Cultures 
and Interventional Management. 2nd World Congress On Interventional Therapies For 
Type 2 Diabetes. 2011: P4. 
[7]  Altieri, P., Garcia Palmieri MR. Sudden Death in Puerto Rico: A United States Caribbean 
Island. Revista Latina de Cardiologia. 1993: 14-17. 
[8]  Marcial J, Altieri PI, Banchs HL, Escobales N, Crespo M. Metabolic Syndrome among 
Puerto Ricans and others Hispanic populations. PRHSJ. 2011; 30 (3): 145-151. 
 
The Metabolic Syndrome in Hispanics – The Role of Insulin Resistance and Inflammation 83 
[9] Altieri P, Figueroa Y, Banchs H, Henandez Gil de Lamadrid, Escobales N, Crespo M. 
Higher incidence of atrial fibrillation in the metabolic syndrome: A Hispanic population 
study. Boletín Asociación Médica de Puerto Rico, Año 103. 2011; 4: 24-27. 
[10] U.S.Government Medical Statistics-2010 
[11] Armal JF, Battle T, Rasetti C, Challah M, Costerousse O, Vincaut E, Michel JB, Alhene-
Gelas F. ACE in three tunicae of rat aorta expression in smooth muscle and effect of 
renovascular hypertension. AMJ Physiol 1994; 267: H1777-H1784 
[12] Woodman ZL, Oppong SY, Cooks Hooper NM, Schwager SL, Brand WF, Ehlers MR, 
Sturrock ED. Shedding of somatic angiotensin converting enzyme (ACE) is inefficient 
compared with testis ACE despite cleavage at identiacal stalk sites. Biochem J. 2000; 
347:711-718. 
[13] Rykl, J., et al. Renal cathepsin G and angiotensin II generation. J Hypertens 24, 1797-1807 
(2006). 
[14] Ocaranza, M.P. & Jalil, J.E. Protective Role of the ACE2/Ang-(1-9) Axis in 
Cardiovascular Remodeling. Int J Hypertens 2012, 594361 (2012). 
[15] Yasunarik K, Kohono M, Kano H, Yakokawa K, Horio T, Yushikawa J. Aldose 
Hyperproliferation and hypertrophy of cultured rat vascular smooth muscle cell 
induced by high glucose. Arterioscler Thromb Vasc Biol. 1995; 15:2207-2212. 
[16] Goldin, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products 
sparking the development of diabetic vascular injury. Circulation. 2006; 114:597-605. 
[17] Guzik T, Mussa S, Gastald D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. 
Machanism of increased vascular superoxide production in human diabetes mellitus. 
Circulation. 2002; 105:1656-1662. 
[18] Crespo, M.J., Cruz, N., Altieri, P.I. & Escobales, N. Enalapril and losartan are more 
effective than carvedilol in preventing dilated cardiomyopathy in the Syrian 
cardiomyopathic hamster. J Cardiovasc Pharmacol Ther 13, 199-206 (2008). 
[19] de Kloet, A.D., Krause, E.G. & Woods, S.C. The renin angiotensin system and the 
metabolic syndrome. Physiol Behav 100, 525-534 (2010). 
[20] Strazzullo, P. & Galletti, F. Impact of the renin-angiotensin system on lipid and 
carbohydrate metabolism. Curr Opin Nephrol Hypertens 13, 325-332 (2004). 
[21] Engeli, S., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 
45, 356-362 (2005). 
[22] Boustany, C.M., et al. Activation of the systemic and adipose renin-angiotensin system 
in rats with diet-induced obesity and hypertension. Am J Physiol Regul Integr Comp 
Physiol 287, R943-949 (2004). 
[23] Rahmouni, K., Mark, A.L., Haynes, W.G. & Sigmund, C.D. Adipose depot-specific 
modulation of angiotensinogen gene expression in diet-induced obesity. Am J Physiol 
Endocrinol Metab 286, E891-895 (2004). 
[24] Fuster V., Badimon JJ, Chesebro JH. The pathogenesis of Coronary Artery Disease and 
Acute Coronary Syndrome. N Engl J Med. Part 1 and 2, 1992; 326, 242-50, 310-8. 
 
Insulin Resistance 84 
[25] Fuster V, Lewis A. Conner Memorial Lecture. Mechanism Leading to Myocardial 
Infarction: In Sights from Studies of Vascular Biology. Circulation. 1994; 90:2126-46. 
[26] Altieri P., Alvarado S., Banchs H., Escobales N., Crespo M. The role of Angiotensin II 
and Endothelin I in the cardiomyopathy of diabetic patients. J Investigative Med 2012; 
81  
[27] Heeneman S, Sluimer J, Daemen Mat JAP. Angiotensin converting enzyme and vascular 
remodeling. Circ Res. 2007; 101:441-454. 
[28] Goldberg IJ, Dansky HM, Diabetic vascular disease. Arterioscler Thromb Vasc. Biol. 2006; 
26:1693-1701. 
[29] Kaschina E, Grzesiak A, Li J, et al. Angiotensin II Type II receptor stimulation. A novel 
option of therapeutic interference with the renin-angiotensin system in myocardial 
infarction. Circulation. 2008; 118:2523-2532. 
[30] Spite M, Serham CN. Novel lipid mediators promote resolution of acute inflammation-
impact of aspirin and statins. Cir Res. 2010; 107:1170-1184. 
[31] Kanes R, Rosuvastatin Inflammation, C-Reactive Protein, Jupiter and Primary 
Prevention of Cardiovascular Disease a Perspective. Drug Des Devel Ther. 2010 Dec 9; 4: 
383-413. 
[32] Elkind MS, Tai Coates K, Daik MC, Saccor L. High Sensitivity C-Reactive Protein, 
Lipoprotein-Associated Phospholipase A 2 and Outcome After Ischemic Stroke. Arch 
Intern Med 2006 Oct 23; 166 (19): 2073-80. 
[33] Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, Walsh K. Obesity, adiponectin and 
vascular inflammatory disease. Curr Opin Lipidol. 2003 Dec;14(6):561-6. 
[34] R Shibata et al. Adiponectin protects against myocardial ischemia-reperfusion  
injury through AMPK- and COX-2–dependent mechanisms. Nat Med 11. 2005; 1096-
1103. 
[35] Davignon J, Jacob RF, Mason RP. The Antioxidant Effect of Statins. Coron Artery Dis. 
2004 Aug; 15(5): 251-8.  
[36] Ouchi, Noriyuki; Higuchi, Akiko; Ohashi, Koji; Oshima, Yuichi; Gokce, Noyan; 
Shibata, Rei; Akasaki, Yuichi; Shimono, Akihiko; Walsh, Kenneth. Sfrp5 Is an Anti-
Inflammatory Adipokine That Modulates Metabolic Dysfunction in Obesity. Science 
2010; 329: 454-457. 
[37] Pittas, A.G., Joseph, N.A. & Greenberg, A.S. Adipocytokines and insulin resistance. J 
Clin Endocrinol Metab 89, 447-452 (2004).. 
[38] Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilizatin in 
the pathogenesis of insulin resistance and Type 2 diabetes. Endocr Rev. 2002; 23:201-
29. 
[39] Sjostrand M, Eriksson JVV. Neuroendocrine mechanisms in insulin resistance. Mol Cell 
Endocrinol. 2009; 297:104-111. 
[40] Altieri P, Albarado S, Banchs H, Escobales N, Crespo M. The role of angiotensin II and 
Endothelin I in the cardiomyopathy of diabetic patients. J Investigative Med. 2012: 81. 
 
The Metabolic Syndrome in Hispanics – The Role of Insulin Resistance and Inflammation 85 
[41] Ridker PM, Buring JE, Cook NR & Rifai N. C-reactive protein, the metabolic syndrome, 
and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially 
healthy American women. Circulation 2003; 107:391-397. 
[42] Sherajee S, Fujita Y, Rafig K, et al. Aldosterone induces vascular insulin like growth 
factor I receptor and hybrid receptor. Arterioscler Thromb Vasc Biol. 2012; 32:257-
263. 
[43] Knutson, K.L. & Van Cauter, E. Associations between sleep loss and increased risk of 
obesity and diabetes. Ann N Y Acad Sci 1129, 287-304 (2008). 
[44] Lumeng, J.C., et al. Shorter sleep duration is associated with increased risk for being 
overweight at ages 9 to 12 years. Pediatrics 120, 1020-1029 (2007). 
[45] Taheri, S., Lin, L., Austin, D., Young, T. & Mignot, E. Short sleep duration is associated 
with reduced leptin, elevated ghrelin, and increased body mass index. PLoS Med 1, e62 
(2004). 
[46] Ayas, N.T., et al. A prospective study of sleep duration and coronary heart disease in 
women. Arch Intern Med 163, 205-209 (2003). 
[47] Challet E, Delezie J. Interactions between metabolism and circadian clocks: reciprocal 
disturbances. An NY Acad Sci. 2011 Dec; 1243:30-46. 
[48] Bo, S., et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A 
randomized controlled trial. J Gen Intern Med 22, 1695-1703 (2007). 
[49] Panagiotakos, D.B., et al. Impact of lifestyle habits on the prevalence of the metabolic 
syndrome among Greek adults from the ATTICA study. Am Heart J 147, 106-112 
(2004). 
[50] Sun A, Spegelman D, Van Dam R et. al. White rice, brown rice, and risk of diabetes type 
2 in U.S. men and women. Arch Inter Med. 2010; 170:961-9. 
[51] Walsh NP, Gleeson M, Pyne DB et. al. Position statement. Part two: Maintaining 
immune health. Exerc Immunol Rev. 2011; 17:64-103. 
[52] Brown, J.M., et al. Combined therapy of dietary fish oil and stearoyl-CoA desaturase 1 
inhibition prevents the metabolic syndrome and atherosclerosis. Arterioscler Thromb 
Vasc Biol 30, 24-30 (2010). 
[53] Buchwald, H., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 292, 
1724-1737 (2004). 
[54] Wolf, A.M. & Colditz, G.A. Current estimates of the economic cost of obesity in the 
United States. Obes Res 6, 97-106 (1998). 
[55] Curtis, L.H., et al. Costs of the metabolic syndrome in elderly individuals: findings from 
the Cardiovascular Health Study. Diabetes Care 30, 2553-2558 (2007). 
[56] Boudreau, D.M., et al. Health care utilization and costs by metabolic syndrome risk 
factors. Metab Syndr Relat Disord 7, 305-314 (2009). 
[57] Ramsay, S.E., Whincup, P.H., Morris, R., Lennon, L. & Wannamethee, S.G. Is 
socioeconomic position related to the prevalence of metabolic syndrome?: influence of 
social class across the life course in a population-based study of older men. Diabetes Care 
31, 2380-2382 (2008). 
 
Insulin Resistance 86 
[58] Liao, G.Y., et al. Dendritically targeted Bdnf mRNA is essential for energy balance and 
response to leptin. Nat Med 18, 564-571 (2012). 
